GVHD Reduced With Vorinostat

TON - February 2013, Vol 6, No 1 published on February 21, 2013 in Conference Correspondent
Caroline Helwick

The administration of the histone deacetylase inhibitor vorinostat in patients undergoing matched related donor reduced-intensity conditioning allogeneic hematopoietic stem cell transplants could be an effective approach to reducing graft-versus-host disease (GVHD), according to the first-in-human clinical trial of 45 patients. The drug was added on days 10 to 100 to standard GVHD prophylaxis consisting of mycophenolate mofetil and tacrolimus.

After treatment, patients who received vorinostat had a significantly lower incidence of GVHD than their historical controls (22% vs 42%). They also had lower rates of grade 3 and 4 GVHD (4% vs 19%) as well as transplant-related mortality at 1 year (13% vs 19%). There were no significant differences in rates of infectious complications or incidence of relapse, indicating that vorinostat helped reduce the risk of GVHD in patients without further compromise.

Reference

Choi SW, DiPersio JF, Braun TM, et al. Targeting histone deacetylases as a new strategy for graft versus host disease prevention. Presented at: 54th American Society of Hematology Annual Meeting; December 8-11, 2012; Atlanta, GA. Abstract 740.

Related Items
Emerging Safety Data with Checkpoint Inhibitors
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Psychological Distress in Patients with Cancer Warrants Attention
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Patients’ Chemotherapy-Related Side-Effect Concerns Have Evolved, But Hair Loss Remains Significant
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Increased Cancer Risk in Postmenopausal Women with Central Obesity
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Patients’ Fears of Radiation Side Effects Largely Unfounded
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Netupitant plus Palonosetron Noninferior to Aprepitant plus Granisetron in Patients Receiving Highly Emetogenic Chemotherapy
Li Zhang, MD
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Patient-Reported Outcomes Influence Radiation Guidelines
Alice Goodman
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Healthy Lifestyle Improves Survival in Patients with Colon Cancer
Phoebe Starr
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Colorectal Cancer, Conference Correspondent
8-Week Internet-Based Psychological Intervention Reduces Stress in Patients Newly Diagnosed with Cancer
Phoebe Starr
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Hair Loss Seen in 1 of 3 Women with Breast Cancer Receiving Endocrine Therapy
Alice Goodman
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Last modified: May 21, 2015